Outpatient Medical Injectable Infliximab Authorization (including biosimilars) - Coverage Criteria
Customize your policy alerts
Sign up for all Highmark Delaware policy alerts
Know when Highmark Delaware releases new policies or updates existing guidance.
Monitor payer policy activity
Form and requirements for prior authorization of outpatient medical benefit infliximab (including biosimilars) for Highmark Delaware members; intended for prescribing clinicians, infusion providers, and billing offices requesting authorization.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.